Premium Multi-Cannabinoid Complex
Our Golden Harvest Hemp ExtractTM contains more than just CBD. A revolutionary extraction process means our multi-cannabinoid products feature a complete range of cannabinoids.
Cannabinoids like CBG, and CBD-V have each been suggested to contain their own unique health benefits.
Most products who advertise a “full-spectrum formula,” may be missing out on these potential benefits as most contain upwards to >95% of just CBD.
In contrast, our multi-cannabinoid blends delivers a fuller range of cannabinoids with CBD, CBG, and CBD-V and at levels far greater than our competitors.
Our Cannabinoids
CBD
- Chronic Pain
- Sleep Disorders
- Multiple Sclerosis
- Antioxidant
CBG
- Colitis
- IBS
- Acne
- Alzheimer’s
CBD-V
- Epilepsy
- Nausea
- Skin Diseases
- Neuroprotect
As Cited Below:
*Current research does not guarantee that phytocannabinoids will cure any condition. However, a growing body of ongoing research does suggest that these phytocannabinoids could offer treatment potential for a variety of physical and mental conditions.
References:
CBD
Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018). Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiology and psychiatric sciences, 1-9.
https://www.ncbi.nlm.nih.gov/pubmed/26260390
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis‐based medicines for chronic neuropathic pain in adults. The Cochrane Library.
https://www.ncbi.nlm.nih.gov/pubmed/29513392
Jensen, B., Chen, J., Furnish, T., & Wallace, M. (2015). Medical marijuana and chronic pain: a review of basic science and clinical evidence. Current pain and headache reports, 19(10), 50.
https://www.ncbi.nlm.nih.gov/pubmed/26325482
Burns, T. L., & Ineck, J. R. (2006). Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Annals of Pharmacotherapy, 40(2), 251-260.
https://www.ncbi.nlm.nih.gov/pubmed/16449552
Brunt, T. M., van Genugten, M., Höner-Snoeken, K., van de Velde, M. J., & Niesink, R. J. (2014). Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. Journal of clinical psychopharmacology, 34(3), 344-349.
Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports, 19(4), 23.
https://www.ncbi.nlm.nih.gov/pubmed/28349316
Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz, 30(1), 47-61.
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current medical research and opinion, 23(1), 17-24.
https://www.ncbi.nlm.nih.gov/books/NBK74699/
Lakhan, S. E., & Rowland, M. (2009). Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC neurology, 9(1), 59.
https://www.ncbi.nlm.nih.gov/pubmed/19961570
Wade, D. T., Collin, C., Stott, C., & Duncombe, P. (2010). Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Multiple Sclerosis Journal, 16(6), 707-714.
https://www.ncbi.nlm.nih.gov/pubmed/20558502
Wright, S., Duncombe, P., & Altman, D. G. (2012). Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach. Trials, 13(1), 189.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487910/
McPartland, J. M., Guy, G. W., & Di Marzo, V. (2014). Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PloS one, 9(3), e89566.
Cuba, L. F., Salum, F. G., Cherubini, K., & Figueiredo, M. A. Z. (2017). Cannabidiol: an alternative therapeutic agent for oral mucositis?. Journal of clinical pharmacy and therapeutics, 42(3), 245-250.
https://www.ncbi.nlm.nih.gov/pubmed/28191662
Martin-Santos, R., Fagundo, A. B., Crippa, J. A., Atakan, Z., Bhattacharyya, S., Allen, P., … & McGuire, P. (2010). Neuroimaging in cannabis use: a systematic review of the literature. Psychological medicine, 40(3), 383-398.
https://www.ncbi.nlm.nih.gov/pubmed/19627647
Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19(3), 293-300.
Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research. 162 (1–3): 153–61.
https://www.ncbi.nlm.nih.gov/pubmed/25667194
Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia research, 162(1-3), 153-161.
https://www.ncbi.nlm.nih.gov/pubmed/25667194
Bostwick, J. M. (2012, February). Blurred boundaries: the therapeutics and politics of medical marijuana. In Mayo Clinic Proceedings (Vol. 87, No. 2, pp. 172-186). Elsevier.
Couch, D. G., Maudslay, H., Doleman, B., Lund, J. N., & O’Sullivan, S. E. (2018). The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflammatory bowel diseases, 24(4), 680-697.
Stockings, E., Zagic, D., Campbell, G., Weier, M., Hall, W. D., Nielsen, S., … & Degenhardt, L. (2018). Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry, 89(7), 741-753.
https://www.ncbi.nlm.nih.gov/pubmed/29511052
Reddy, D. S., & Golub, V. M. (2016). The pharmacological basis of cannabis therapy for epilepsy. Journal of Pharmacology and Experimental Therapeutics, 357(1), 45-55.
Sultan, S. R., Millar, S. A., England, T. J., & O’Sullivan, S. E. (2017). A systematic review and meta-analysis of the haemodynamic effects of Cannabidiol. Frontiers in pharmacology, 8, 81.
Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., & Jutras-Aswad, D. (2015). Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics, 12(4), 807-815.
https://www.ncbi.nlm.nih.gov/pubmed/26269227
Prud’homme, M., Cata, R., & Jutras-Aswad, D. (2015). Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance abuse: research and treatment, 9, SART-S25081.
Marco, E. M., García-Gutiérrez, M. S., Bermúdez-Silva, F. J., Moreira, F., Guimarães, F., Manzanares, J., & Viveros, M. P. (2011). Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Frontiers in behavioral neuroscience, 5, 63.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186912/
Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals, 5(5), 529-552.
https://www.ncbi.nlm.nih.gov/pubmed/24281562
Crippa, J. A., Derenusson, G. N., Chagas, M. H., Atakan, Z., Martín-Santos, R., Zuardi, A. W., & Hallak, J. E. (2012). Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm reduction journal, 9(1), 7.
Stern, C. A., Gazarini, L., Takahashi, R. N., Guimaraes, F. S., & Bertoglio, L. J. (2012). On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology, 37(9), 2132.
Liou, G. I. (2010). Diabetic retinopathy: role of inflammation and potential therapies for anti-inflammation. World journal of diabetes, 1(1), 12.
Le Foll, B., Trigo, J. M., Sharkey, K. A., & Le Strat, Y. (2013). Cannabis and Δ 9-tetrahydrocannabinol (THC) for weight loss?. Medical hypotheses, 80(5), 564-567.
CBG
Couch, D. G., Maudslay, H., Doleman, B., Lund, J. N., & O’Sullivan, S. E. (2018). The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflammatory bowel diseases, 24(4), 680-697.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., … & Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical pharmacology, 85(9), 1306-1316.
Giacoppo, S., Gugliandolo, A., Trubiani, O., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2017). Cannabinoid CB2 receptors are involved in the protection of RAW264. 7 macrophages against the oxidative stress: an in vitro study. European journal of histochemistry: EJH, 61(1).
https://www.ncbi.nlm.nih.gov/pubmed/27094344
Pucci, M., Rapino, C., Di Francesco, A., Dainese, E., D’addario, C., & Maccarrone, M. (2013). Epigenetic control of skin differentiation genes by phytocannabinoids. British journal of pharmacology, 170(3), 581-591.
Fernández-Ruiz, J; Moro, M. A; Martínez-Orgado, J (2015). “Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications”. Neurotherapeutics. 12 (4): 793–806. doi:10.1007/s13311-015-0381-7
https://www.ncbi.nlm.nih.gov/pubmed/26260390
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185-199.
Smeriglio, A., Giofrè, S. V., Galati, E. M., Monforte, M. T., Cicero, N., D’Angelo, V., … & Circosta, C. (2018). Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. Fitoterapia, 127, 101-108.
Giacoppo, S., Gugliandolo, A., Trubiani, O., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2017). Cannabinoid CB2 receptors are involved in the protection of RAW264. 7 macrophages against the oxidative stress: an in vitro study. European journal of histochemistry: EJH, 61(1).
Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., … & Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. Journal of natural products, 71(8), 1427-1430.
Wilkinson, J. D., & Williamson, E. M. (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of dermatological science, 45(2), 87-92.
Colasanti, B. K., Craig, C. R., & Allara, R. D. (1984). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Experimental eye research, 39(3), 251-259.
Baek, S. H., Kim, Y. O., Kwag, J. S., Choi, K. E., & Jung, W. Y. (1998). Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Archives of pharmacal research, 21(3), 353.
https://www.ncbi.nlm.nih.gov/pubmed/9875457
Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., … & Izzo, A. A. (2014). Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35(12), 2787-2797.
CBDV
Amada N, Yamasaki Y, Williams CM, Whalley BJ (2013). “Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression”. PeerJ. 1: e214. doi:10.7717/peerj.214
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840466/
Iannotti, F. A., Hill, C. L., Leo, A., Alhusaini, A., Soubrane, C., Mazzarella, E., … & Stephens, G. J. (2014). Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS chemical neuroscience, 5(11), 1131-1141.
https://www.ncbi.nlm.nih.gov/pubmed/25029033
Hill, A. J., Mercier, M. S., Hill, T. D. M., Glyn, S. E., Jones, N. A., Yamasaki, Y., … & Williams, C. M. (2012). Cannabidivarin is anticonvulsant in mouse and rat. British journal of pharmacology, 167(8), 1629-1642.
https://www.ncbi.nlm.nih.gov/pubmed/22970845
Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & Behavior, 70, 319-327.
https://www.ncbi.nlm.nih.gov/pubmed/28190698
Gaston, T. E., & Friedman, D. (2017). Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy & Behavior, 70, 313-318.
https://www.ncbi.nlm.nih.gov/pubmed/28087250
Hill, T. D. M., Cascio, M. G., Romano, B., Duncan, M., Pertwee, R. G., Williams, C. M., … & Hill, A. J. (2013). Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism. British journal of pharmacology, 170(3), 679-692.
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015). Cannabinoids and epilepsy. Neurotherapeutics, 12(4), 747-768.
Oláh, A., Markovics, A., Szabó‐Papp, J., Szabó, P. T., Stott, C., Zouboulis, C. C., & Bíró, T. (2016). Differential effectiveness of selected non‐psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Experimental dermatology, 25(9), 701-707.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & therapeutics, 133(1), 79-97.